DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Phase 2

Recruiting

Conditions: Generalized Anxiety Disorder (GAD)

Interventions: Drug: Placebo for ABBV-932
Drug: ABBV-932
Drug: Antidepressant Therapy (ADT)

First Posted Date: 2025-02-26

Last Posted Date: 2025-05-13

Lead Sponsor: AbbVie

Target Recruit Count: 315

Registration Number: NCT06846320

Locations: 🇺🇸
Viking Clinical Research Center - Temecula /ID# 268598, Temecula, California, United States
🇺🇸
Sunwise Clinical Research /ID# 267863, Walnut Creek, California, United States
🇺🇸
Connecticut Clinical Research - Cromwell /ID# 271241, Cromwell, Connecticut, United States

and more 7 locations

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

Recruiting

Conditions: Ulcerative Colitis

First Posted Date: 2025-02-21

Last Posted Date: 2025-04-23

Lead Sponsor: AbbVie

Target Recruit Count: 80

Registration Number: NCT06838845

Locations: 🇨🇳
The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997, Guangzhou, Guangdong, China
🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753, Guangzhou, Guangdong, China
🇨🇳
The Second Affiliated Hospital Of Zhengzhou University /ID# 274754, Zhengzhou, Henan, China

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Phase 1

Recruiting

Conditions: Glabellar Lines

Interventions: Drug: AGN-151586
Drug: OnabotulinumtoxinA
Drug: Placebo

First Posted Date: 2025-02-19

Last Posted Date: 2025-05-07

Lead Sponsor: AbbVie

Target Recruit Count: 126

Registration Number: NCT06834789

Locations: 🇺🇸
Investigate MD /ID# 270771, Scottsdale, Arizona, United States
🇺🇸
Marcus Facial Plastic Surgery /ID# 270770, Redondo Beach, California, United States
🇺🇸
Skin Research Institute LLC /ID# 270831, Coral Gables, Florida, United States

and more 5 locations

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Recruiting

Conditions: Diffuse Large B-cell Lymphoma
Follicular Lymphoma

First Posted Date: 2025-02-17

Last Posted Date: 2025-05-16

Lead Sponsor: AbbVie

Target Recruit Count: 700

Registration Number: NCT06830759

Locations: 🇨🇦
Cross Cancer Institute /ID# 271504, Edmonton, Alberta, Canada
🇨🇦
Health Sciences North /ID# 274738, Sudbury, Ontario, Canada
🇬🇷
Evangelismos Hospital /ID# 272736, Athens, Attiki, Greece

and more 5 locations

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

Phase 3

Recruiting

Conditions: Primary Open Angle Glaucoma

First Posted Date: 2025-02-12

Last Posted Date: 2025-05-13

Lead Sponsor: AbbVie

Target Recruit Count: 130

Registration Number: NCT06822738

Locations: 🇺🇸
Mid Atlantic Retina /ID# 268569, Philadelphia, Pennsylvania, United States
🇺🇸
Arizona Advanced Eye Research Institute /ID# 268363, Glendale, Arizona, United States
🇺🇸
LA Glaucoma Group /ID# 268444, Culver City, California, United States

and more 8 locations

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Telisotuzumab Adizutecan
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Panitumumab
Drug: Bevacizumab

First Posted Date: 2025-02-11

Last Posted Date: 2025-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 390

Registration Number: NCT06820463

Locations: 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 268007, Jerusalem, Israel
🇮🇱
Rabin Medical Center /ID# 268008, Petah Tikva, Israel
🇺🇸
Yale New Haven Hospital /ID# 270565, New Haven, Connecticut, United States

and more 7 locations

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Phase 3

Recruiting

Conditions: Chronic Migraine

Interventions: Drug: Atogepant
Drug: Placebo for Atogepant

First Posted Date: 2025-02-05

Last Posted Date: 2025-05-20

Lead Sponsor: AbbVie

Target Recruit Count: 420

Registration Number: NCT06810505

Locations: 🇺🇸
Rehabilitation & Neurological Services /ID# 270782, Huntsville, Alabama, United States
🇺🇸
Preferred Research Partners /ID# 270389, Little Rock, Arkansas, United States
🇺🇸
Neuro Pain Medical Center /ID# 271048, Fresno, California, United States

and more 22 locations

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Phase 3

Recruiting

Conditions: Menstrual Migraine (MM)

Interventions: Drug: Atogepant
Drug: Placebo for Atogepant

First Posted Date: 2025-02-04

Last Posted Date: 2025-05-20

Lead Sponsor: AbbVie

Target Recruit Count: 430

Registration Number: NCT06806293

Locations: 🇨🇳
Chinese PLA General Hospital /ID# 267141, Beijing, Beijing, China
🇨🇳
Nanfang Hospital - Southern Medical University /ID# 268510, Guangzhou, Guangdong, China
🇨🇳
Hebei General Hospital /ID# 267663, Shijiazhuang, Hebei, China

and more 68 locations

A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants

Phase 3

Active, not recruiting

Conditions: Forehead Lines

Interventions: Drug: OnabotulinumtoxinA
Drug: Placebo

First Posted Date: 2025-01-27

Last Posted Date: 2025-04-20

Lead Sponsor: AbbVie

Target Recruit Count: 150

Registration Number: NCT06794866

Locations: 🇯🇵
Tokai University Hospital /ID# 268496, Isehara, Kanagawa, Japan
🇯🇵
Queen's Square Medical Center, Dermatology and Allergology /ID# 268454, Yokohama-shi, Kanagawa, Japan
🇯🇵
Jun Clinic /ID# 268531, Nagano-Shi, Nagano, Japan

and more 12 locations

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Phase 4

Recruiting

Conditions: Facial Contouring

Interventions: Drug: OnabotulinumtoxinA
Device: JUVÉDERM
Device: CoolSculpting Elite System
Other: SkinMedica Products
Drug: KYBELLA

First Posted Date: 2025-01-20

Last Posted Date: 2025-04-09

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT06783621

Locations: 🇺🇸
Center for Dermatology and Dermatologic Surgery /ID# 270390, Washington, District of Columbia, United States
🇺🇸
Marcus Facial Plastic Surgery /ID# 270408, Redondo Beach, California, United States
🇺🇸
Pacific Clinical Innovations /ID# 270414, Vista, California, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy